References

1. Dubuisson J, Helle F, Cocquerel L (2008) Early steps of the hepatitis C virus life cycle. Cellular Microbiology 10: 821-827. View
2. Ghany MG, Strader DB, Thomas DL, Seeff LB, American Association for the Study of Liver Diseases, et al. (2009) Diagnosis, management, and treatment of hepatitis C: AN UPDATE. Hepatology 49: 1335-1374. View
3. Fattovich G, Llovet JM (2006) Risk factors for hepatocellular carcinoma in HCV-cirrhosis: what we know and what is missing. J Hepatol 44: 1013- 1016. View
4. Younossi Z, Park H, Henry L, Adeyemi A, Stepanova M, et al. (2016) Extrahepatic manifestations of hepatitis C: A meta-analysis of prevalence, quality of life, and economic burden. Gastroenterology 150: 1599-1608. View
5. El-Serag HB, Hampel H, Yeh C, Rabeneck L (2002) Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology 36: 1439-1445. View
6. Gheith OAA (2011) Dilemma of HCV ınfection in renal transplant recipients. International Journal of Nephrology. View
7. Örmeci N, Malhan S, Balık İ, Ergör G, Razavi H, et al. (2017) Scenarios to manage the hepatitis C disease burden and associated economic impact of treatment in Turkey. Hepatol Int 11: 509-516. View
8. Hu KQ, Tong MJ (1999) The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology. 29: 1311-1316. View
9. Butt AA, Skanderson M, McGinnis KA, Ahuja T, Bryce CL, et al. (2007) Impact of hepatitis C virus infection and other comorbidities on survival in patients on dialysis. J Viral Hepat 14: 688-696. View
10. Pisoni RL, Gillespie BW, Dickinson DM, Chen K, Kutner MH, et al. (2004) The dialysis outcomes and practice patterns study (DOPPS): design, data elements, and methodology. Am J Kidney Dis 44: S7-S15. View
11. Fabrizi F, Dixit V, Messa P (2012) Impact of hepatitic C on survival in dialysis patients: a link with cardiovascular mortality? Journal of Viral Hepatitis 19: 601-607. View
12. Chen YC, Lin HY, Li CY, Lee MS, Su YC, et al. (2014) A nationwide cohort study suggests that hepatitis C virus infection is associated with increased risk of chronic kidney disease. Kidney International 85: 1200-1207. View
13. Fabrizi F, Penatti A, Messa P, Martin P (2014) Treatment of hepatitis C after kidney transplant: A pooled analysis of observational studies. Journal of Medical Virology 86: 933-940. View
14. Fabrizi F, Verdesca S, Messa P, Martin P (2016) Hepatitis C virus ıncreases the risk of kidney disease among HIV-positive patients: systematic review and meta-analysis. Journal of Medical Virology 88: 487-497. View
15. Tsui JI, Vittinghoff E, Shlipak MG, Bertenthal D, Inadomi J, et al. (2007) Association of hepatitis C seropositivity with ıncreased risk for developing end-stage renal disease. Arch Intern Med 167: 1271-1276. View
16. Kirsztajn GM, Filho NS, Draibe SA, Netto MV, Thome FS, et al. (2014) Fast reading of the KDIGO 2012: guidelines for evaluation and management of chronic kidney disease in clinical practice. J Bras Nefrol 36: 63-73. View
17. Pol S, Jadoul M, Vallet-Pichard A (2017) An update on the management of hepatitis C virus-infected patients with stage 4-5 chronic kidney disease while awaiting the revised KDIGO guidelines. Nephrol Dial Transplant 32: 32-35. View
18. Morales JM, Campistol JM, Domínguez-Gil B, Andrés A, Esforzado N, et al. (2010) Long-term experience with kidney transplantation from hepatitis C-positive donors into hepatitis C-positive recipients. American Journal of Transplantation 10: 2453-2462. View
19. Gallegos-Orozco JF, Kim R, Thiesset HF, Hatch J, Lynch k, et al. (2016) Early results of pilot study using hepatitis C virus (HCV) positive kidneys to transplant HCV infected patients with end-stage renal disease allowing for successful interferon-free direct acting antiviral therapy after transplantation 8: 890. View
20. Park H, Adeyemi A, Henry L, Stepanova M, Younossi Z, et al. (2015) A meta-analytic assessment of the risk of chronic kidney disease in patients with chronic hepatitis C virus infection. Journal of Viral Hepatitis 22: 897- 905. View
21. Ladino M, Pedraza F, Roth D (2017) Opportunities for treatment of the hepatitis C virus-infected patient with chronic kidney disease. World J Hepatol 9: 833-839. View
22. Lens S, Rodriguez-Tajes S, Llovet LP, Maduell F, Londoño MC, et al. (2017) Treating hepatitis C in patients with renal failure. Dig. Dis 35: 339-346. View
23. HCV Guidance recommendations for testing, managing and treating hepatitis C. Infectious Diseases Society of America. View
24. European association for the study of the liver (2016) EASL recommendations on treatment of hepatitis C 2016. Journal of Hepatology. View
25. Omata M, Kanda T, Wei L, Yu ML, Chuang WL, et al. (2016) APASL consensus statements and recommendation on treatment of hepatitis C. Hepatol Int 10: 702-726. View
26. Pillai AA, Maheshwari R, Vora R, Norvell JP, Ford R, et al. (2017) Treatment of HCV infection in liver transplant recipients with ledipasvir and sofosbuvir without ribavirin. Aliment PharmacolTher 45: 1427-1432. View
27. Saxena V, Koraishy FM, Sise ME, Lim JK, Schmidt M, et al. (2016) Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. Liver Int 36: 807-816. View
28. Liu CH, Liang CC, Lin JW, Chen SI, Tsai HB, et al. (2008) Pegylated interferon Alfa-2a versus standart interferon alfa-2a for treatment-naive dialysis patients with chronic hepatitis C: a randomised study. Gut 57: 525- 530. View
29. Basu P, Siriki R, Shah NJ, Farhat S, Mittimani K, et al. (2013) Telaprevir with adjusted dose of ribavirin in naive CHC-G1: efficacy ant treatment in CHC in hemodialysis population. J Hepatol. 58: S30-S31. View
30. Sperl J, Frankova S, Kreidlova M, Merta D, Tothova M, et al. (2017) Combination of sofosbuvir and daclatasvir in the treatment of genotype 3 chronic hepatitis C virus infection in patients on maintenance hemodialysis. Therapeutics and clinical risk management. 13: 733-738. View
31. Taneja S, Duseja A, De A, Kumar V, Ramchandran R, et al. (2017) Successful treatment of chronic hepatitis C infection with directly acting antivirals in renal transplant recipients. View
32. Reddy KR, Roth D, Bruchfeld A, Hwang P, Haber B, et al. (2017) Elbasvir/ grazoprevir does not worsen renal function in patients with hepatitis C virus infection and pre-existing renal disease. Hepatology Research 47: 1340- 1345. View
33. Ip S, Hussaini T, Daulat A, Partovi N, Erb SR, et al. (2017) Interaction of gender and hepatitis C in risk of chronic renal failure after liver transplantation. Annals of Hepatology 16: 230-235. View
34. Suda G, Nagasaka A, Yamamoto Y, Furuya K, Kumagai K, et al. (2017) Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virusınfected patients with renal impairment. Hepatol Res 47: 1127-1136. View
35. Li T, Qu Y, Guo Y, Wang Y, Wang L, et al. (2017) Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C Virus patients with stage 4-5 chronic kidney disease: A meta-analysis. Liver International 37: 974-981. View
36. Ponziani FR, Siciliano M, Lionetti R, Pasquazzi C, Gianserra L, et al. (2017) Effectiveness of paritaprevir/ritonavir/ombitasvir/dasabuvir in hemodialysis patients with hepatitis C virus infection and advanced liver fibrosis: case reports. Am J Kidney Dis 70: 297-300. View
37. Pockros PJ, Reddy KR, Mantry PS, Cohen E, Bennett M, et al. (2016) Efficacy of direct-acting antiviral combination for patients with hepatitis C virus genotype 1 infection and severe renal impairment or end-stage renal disease. Gastroenterology 150: 1590-1598. View
38. Nazario HE, Ndungu M, Modi AA (2016) Sofosbuvir and simeprevir in hepatitis C genotype 1-patients with end-stage renal disease on haemodialysis or GFR<30 mlmin. liver int 36: 798-801. View
39. Lubetzky M, Chun S, Joelson A, Coco M, Kamal L, et al. (2017) Safety and efficacy of treatment of hepatitis C in kidney transplant recipients with directly acting antiviral agents. Transplantation 101: 1704-1710. View
40. Muñoz-Gómez R, Rincón D, Ahumada A, Hernández E, Devesa MJ, et al. (2017) Therapy with ombitasvir / paritaprevir / ritonavir plus dasabuvir is effective and safe for the treatment of genotypes 1 and 4 hepatitis C virus (HCV) infection in patients with severe renal impairment: A multicentre experience. J Viral Hepat 24: 464-471. View
41. Roth D, Nelson DR, Bruchfeld A, Liapakis A, Silva M, et al. (2015) Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet 386: 1537-1545. View
42. Gane E, Lawitz E, Pugatch D, Papatheodoridis G, Brau N, et al. (2017) Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment. N. Engl J Med 377: 1448-1455. View